Back

Air plasma-activated medium exerts tumor-specific cytotoxicity via the oxidative stress-induced perinuclear mitochondrial clustering

Suzuki-Karasaki, M.; Ando, T.; Ochiai, Y.; Kawahara, K.; Suzuki-Karasaki, M.; Nakayama, H.; Suzuki-Karasaki, Y.

2021-11-01 cancer biology
10.1101/2021.10.31.466636 bioRxiv
Show abstract

Intractable cancers such as osteosarcoma (OS) and oral cancer (OC) are highly refractory, recurrent, and metastatic once developed, and their prognosis is still disappointing. Tumor-targeted therapy eliminating cancers effectively and safely is the current clinical choice. Since aggressive tumors have inherent or acquired resistance to multidisciplinary therapies targeting apoptosis, tumor-specific induction of another cell death modality is a promising avenue to meet the goal. Here, we report that a cold atmospheric air plasma-activated medium (APAM) can induce cell death in OS and OC via a unique mitochondrial clustering. This event was named monopolar perinuclear mitochondrial clustering (MPMC) because of the characteristic unipolar mitochondrial perinuclear aggregation. APAM had potent antitumor activity both in vitro and in vivo. APAM caused apoptosis, necrotic cell death, and autophagy. APAM contained hydrogen peroxide and increased mitochondrial ROS (mROS), while the antioxidant N-acetylcysteine (NAC) prevented cell death. MPMC occurred following mitochondrial fragmentation coinciding with nuclear damages. MPMC was accompanied by the tubulin network remodeling and mitochondrial lipid peroxide (mLPO) accumulation and prevented by NAC and the microtubule inhibitor, Nocodazole. Increased Cardiolipin (CL) oxidation was also seen, and NAC and the peroxy radical scavenger Ferrostatin-1 prevented it. In contrast, in fibroblasts, APAM induced minimal cell death, mROS generation, mLPO accumulation, CL oxidation, and MPMC. These results suggest that MPMC is a tumor-specific cause of cell death via mitochondrial oxidative stress and microtubule-driven mitochondrial motility. MPMC might serve as a promising target for exerting tumor-specific cytotoxicity. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=120 SRC="FIGDIR/small/466636v1_ufig1.gif" ALT="Figure 1"> View larger version (20K): org.highwire.dtl.DTLVardef@1118e2corg.highwire.dtl.DTLVardef@18cf99corg.highwire.dtl.DTLVardef@57a7edorg.highwire.dtl.DTLVardef@d1f447_HPS_FORMAT_FIGEXP M_FIG Graphical abstract C_FIG

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Cell Death & Disease
126 papers in training set
Top 0.1%
36.4%
2
Cell Death Discovery
58 papers in training set
Top 0.1%
5.5%
3
Cancers
213 papers in training set
Top 2%
4.1%
4
Translational Oncology
21 papers in training set
Top 0.1%
3.2%
5
Free Radical Biology and Medicine
36 papers in training set
Top 0.2%
2.8%
50% of probability mass above
6
Frontiers in Oncology
103 papers in training set
Top 1%
2.5%
7
Scientific Reports
3612 papers in training set
Top 43%
2.4%
8
International Journal of Molecular Sciences
494 papers in training set
Top 6%
2.1%
9
Redox Biology
70 papers in training set
Top 0.5%
2.1%
10
Neoplasia
23 papers in training set
Top 0.2%
2.0%
11
Molecular Oncology
55 papers in training set
Top 0.6%
1.7%
12
Theranostics
37 papers in training set
Top 0.4%
1.7%
13
Cell Death & Differentiation
48 papers in training set
Top 0.6%
1.5%
14
PLOS ONE
5266 papers in training set
Top 52%
1.4%
15
iScience
1154 papers in training set
Top 22%
1.3%
16
Cells
249 papers in training set
Top 5%
1.1%
17
eLife
5828 papers in training set
Top 57%
1.1%
18
Acta Biochimica et Biophysica Sinica
23 papers in training set
Top 0.4%
1.1%
19
Biochemistry and Biophysics Reports
30 papers in training set
Top 0.7%
1.1%
20
Frontiers in Molecular Biosciences
102 papers in training set
Top 1%
1.1%
21
Cancer Letters
35 papers in training set
Top 0.9%
1.0%
22
Oncogene
85 papers in training set
Top 1%
1.0%
23
mBio
833 papers in training set
Top 11%
0.8%
24
Communications Biology
993 papers in training set
Top 29%
0.8%
25
British Journal of Cancer
49 papers in training set
Top 2%
0.8%
26
Molecular Cancer Therapeutics
40 papers in training set
Top 0.8%
0.8%
27
Molecules
39 papers in training set
Top 1%
0.8%
28
Journal of Clinical Investigation
179 papers in training set
Top 6%
0.6%
29
Biomedicine & Pharmacotherapy
42 papers in training set
Top 2%
0.6%
30
The FEBS Journal
93 papers in training set
Top 2%
0.6%